Vivoryon Therapeutics NV (VVY) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.838x

Based on the latest financial reports, Vivoryon Therapeutics NV (VVY) has a cash flow conversion efficiency ratio of -0.838x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.96 Million ≈ $-4.63 Million USD) by net assets (€4.73 Million ≈ $5.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Vivoryon Therapeutics NV for the company's overall valuation and market capitalisation.

Vivoryon Therapeutics NV - Cash Flow Conversion Efficiency Trend (2011–2025)

This chart illustrates how Vivoryon Therapeutics NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Vivoryon Therapeutics NV (VVY) share price today for real-time trading data and today's change.

Vivoryon Therapeutics NV Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Vivoryon Therapeutics NV ranked by their cash flow conversion efficiency. Review VVY financial flexibility score to assess the company's free cash flow relative to its total liabilities.

Company	Cash Flow Conversion Efficiency
Essar Shipping Limited NSE:ESSARSHPNG	-0.003x
Kyung Chang Industrial Co. Ltd KQ:024910	0.105x
Monnari Trade S.A. WAR:MON	-0.026x
Eternal Energy Public Company Limited BK:EE	-0.078x
Geekay Wires Limited NSE:GEEKAYWIRE	0.061x
Relief Therapeutics Holding AG SW:RLF	-0.115x
Israel Acquisitions Corp Class A NASDAQ:ISRL	0.043x
KL-Net Corp KQ:039420	0.044x

Annual Cash Flow Conversion Efficiency for Vivoryon Therapeutics NV (2011–2025)

The table below shows the annual cash flow conversion efficiency of Vivoryon Therapeutics NV from 2011 to 2025. Also see VVY total assets for a full breakdown of the balance sheet.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€4.73 Million ≈ $5.53 Million	€-8.46 Million ≈ $-9.88 Million	-1.789x	+26.49%
2024-12-31	€7.88 Million ≈ $9.21 Million	€-19.17 Million ≈ $-22.42 Million	-2.433x	-196.88%
2023-12-31	€26.28 Million ≈ $30.73 Million	€-21.54 Million ≈ $-25.18 Million	-0.820x	+0.32%
2022-12-31	€26.51 Million ≈ $30.99 Million	€-21.79 Million ≈ $-25.48 Million	-0.822x	-20.93%
2021-12-31	€16.56 Million ≈ $19.36 Million	€-11.26 Million ≈ $-13.16 Million	-0.680x	-27.23%
2020-12-31	€26.22 Million ≈ $30.66 Million	€-14.01 Million ≈ $-16.38 Million	-0.534x	-96.41%
2019-12-31	€42.66 Million ≈ $49.88 Million	€-11.61 Million ≈ $-13.57 Million	-0.272x	+95.22%
2018-12-31	€1.23K ≈ $1.44K	€-6.99K ≈ $-8.18K	-5.686x	-318.73%
2017-12-31	€8.92K ≈ $10.43K	€-12.12K ≈ $-14.17K	-1.358x	-67.77%
2016-12-31	€16.38K ≈ $19.15K	€-13.26K ≈ $-15.50K	-0.809x	-7.50%
2015-12-31	€16.13K ≈ $18.86K	€-12.15K ≈ $-14.20K	-0.753x	-13.56%
2014-12-31	€15.97K ≈ $18.67K	€-10.59K ≈ $-12.38K	-0.663x	-132.85%
2013-12-31	€-4.22 Million ≈ $-4.94 Million	€-8.53 Million ≈ $-9.97 Million	2.018x	+189.94%
2012-12-31	€5.37 Million ≈ $6.27 Million	€-12.04 Million ≈ $-14.08 Million	-2.244x	-134.20%
2011-12-31	€14.95 Million ≈ $17.47 Million	€-14.32 Million ≈ $-16.74 Million	-0.958x	--

About Vivoryon Therapeutics NV

AS:VVY Netherlands Biotechnology

Market Cap

$36.35 Million

€31.10 Million EUR

Market Cap Rank

#23146 Global

#84 in Netherlands

Share Price

€1.05

Change (1 day)

+0.96%

52-Week Range

€1.00 - €1.67

All Time High

€26.50